The field of cellular immunotherapy has undergone a profound transformation in recent years, with autologous chimeric antigen receptor (CAR) T-cell therapies emerging as the standard-of-care option ...

The US Environmental Protection Agency (EPA) plans to abandon landmark regulations limiting airborne mercury and greenhouse ...

Over the past decade, several novel immunotherapies have transformed the treatment landscape of relapsed or refractory B-cell acute lymphoblastic leukaemia. In the pivotal TOWER trial, blinatumomab—a ...

The administration of US President Donald Trump has launched a full-fledged assault on science and public health;1 its “flood the zone” strategy created chaos and initially overwhelmed potential ...

Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...